PE5596A1 - Agente antivirosico - Google Patents

Agente antivirosico

Info

Publication number
PE5596A1
PE5596A1 PE1994253128A PE25312894A PE5596A1 PE 5596 A1 PE5596 A1 PE 5596A1 PE 1994253128 A PE1994253128 A PE 1994253128A PE 25312894 A PE25312894 A PE 25312894A PE 5596 A1 PE5596 A1 PE 5596A1
Authority
PE
Peru
Prior art keywords
antivirosico
agent
flavine
virosic
schizoflavine
Prior art date
Application number
PE1994253128A
Other languages
English (en)
Inventor
Washington Odur Ayuko
Original Assignee
Radopath Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Radopath Ltd filed Critical Radopath Ltd
Publication of PE5596A1 publication Critical patent/PE5596A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

SE REFIERE A UN COMPUESTO DERIVADO DE FLAVINA TAL COMO RIBOFLAVINA, LUMICROMO, ESQUIZOFLAVINA, FLAVINA ADENINA DINUCLEOTIDO, 8-HIDROXIFLAVINA, ALOXACINA Y OTROS; QUE ADMINISTRADO EN UNA DOSIS DE POR LO MENOS 10 mg/Kg DE PESO CORPORAL POR DIA, PODRIA SER UTIL EN EL TRATAMIENTO DE INFECCIONES VIROSICAS Y EN PARTICULAR DE HIV
PE1994253128A 1993-10-19 1994-10-19 Agente antivirosico PE5596A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB939321558A GB9321558D0 (en) 1993-10-19 1993-10-19 Anti-viral agents

Publications (1)

Publication Number Publication Date
PE5596A1 true PE5596A1 (es) 1996-04-18

Family

ID=10743784

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1994253128A PE5596A1 (es) 1993-10-19 1994-10-19 Agente antivirosico

Country Status (26)

Country Link
EP (1) EP0739208A1 (es)
JP (1) JPH09505804A (es)
CN (1) CN1140992A (es)
AP (1) AP620A (es)
AU (1) AU7943794A (es)
BG (1) BG100599A (es)
BR (1) BR9407862A (es)
CA (2) CA2123825A1 (es)
CO (1) CO4520283A1 (es)
CZ (1) CZ113796A3 (es)
EE (1) EE9600057A (es)
GB (2) GB9321558D0 (es)
HR (1) HRP940688A2 (es)
HU (1) HUT76322A (es)
IL (1) IL111338A0 (es)
JO (1) JO1866B1 (es)
MA (1) MA23356A1 (es)
MD (1) MD960168A (es)
NO (1) NO961547L (es)
OA (1) OA10579A (es)
PE (1) PE5596A1 (es)
PL (1) PL314008A1 (es)
SK (1) SK50696A3 (es)
UY (1) UY23844A1 (es)
WO (1) WO1995011028A1 (es)
ZA (1) ZA948191B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07188052A (ja) * 1993-12-27 1995-07-25 Sanwa Kagaku Kenkyusho Co Ltd インターフェロン用作用効果増強剤及び該増強剤とインターフェロンとを含有する抗ウイルス活性増強組成物
US5756479A (en) * 1994-12-29 1998-05-26 Research Development Foundation Flavin adenine dinucleotide analogue inhibitors of monoamine oxidase
US7498156B2 (en) 1998-07-21 2009-03-03 Caridianbct Biotechnologies, Llc Use of visible light at wavelengths of 500 to 550 nm to reduce the number of pathogens in blood and blood components
US7049110B2 (en) 1998-07-21 2006-05-23 Gambro, Inc. Inactivation of West Nile virus and malaria using photosensitizers
US7094378B1 (en) 2000-06-15 2006-08-22 Gambro, Inc. Method and apparatus for inactivation of biological contaminants using photosensitizers
US7220747B2 (en) 1999-07-20 2007-05-22 Gambro, Inc. Method for preventing damage to or rejuvenating a cellular blood component using mitochondrial enhancer
US9044523B2 (en) 2000-06-15 2015-06-02 Terumo Bct, Inc. Reduction of contaminants in blood and blood products using photosensitizers and peak wavelengths of light
AU2003299486A1 (en) * 2002-05-10 2004-06-03 The Ohio State University Flavin n-oxides: new anti-cancer agents and pathogen eradication agents
ITTO20020622A1 (it) 2002-07-16 2004-01-16 Dayco Europe Srl Gruppo integrato puleggia-smorzatore torsionale
US20060293335A1 (en) * 2002-08-02 2006-12-28 Qishou Xu Riboflavin derivative and its manufacture and uses
EP2545788A1 (de) * 2011-07-13 2013-01-16 Martin Hulliger Diätisches Mehrkomponentensystem
JP2018131410A (ja) * 2017-02-15 2018-08-23 ヒノキ新薬株式会社 カスパーゼ−３阻害剤とその用途
RU2020116649A (ru) * 2017-10-24 2021-11-30 Лунелла Байотек, Инк. Митофлавосцины: нацеливание на флавин-содержащие ферменты устраняет злокачественные стволовые клетки (cscs) посредством ингибирования митохондриального дыхания
CN114126603A (zh) * 2019-07-09 2022-03-01 帝斯曼知识产权资产管理有限公司 用核黄素或dha降低艾拉弗德的病毒活性

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4219545A (en) * 1979-03-23 1980-08-26 Collins Calvin E Treatment of infectious keratoconjunctivitis in animals
US4264601A (en) * 1979-06-12 1981-04-28 The Board Of Regents Of The University Of Oklahoma Antihypertensive agents and their use in treatment of hypertension
US4500524A (en) * 1982-09-15 1985-02-19 Trustees Of Boston University Tranquilizing and reducing or preventing seizures
WO1991002529A2 (en) * 1989-08-14 1991-03-07 John Bennett Kizer Product and method for killing abnormal vertebrate cells
JP2727471B2 (ja) * 1989-09-14 1998-03-11 三井農林株式会社 インフルエンザウィルス感染予防剤
US5192264A (en) * 1989-10-06 1993-03-09 The Beth Israel Hospital Association Methods and apparatus for treating disease states using oxidized lipoproteins
US5217716A (en) * 1990-07-18 1993-06-08 The Beth Israel Hospital Association Method for treating viral infections using oxidized lipoproteins
FR2674753B1 (fr) * 1991-04-02 1995-03-10 Jean Berque Nouvelles indications therapeutiques, en particulier pour le traitement du sida, d'un medicament deja existant et fabrique a partir d'une molecule denuee de contre-indications et d'effets indesirables.
NZ244270A (en) * 1991-09-13 1995-07-26 Eisai Co Ltd Injectable composition comprising riboflavin
WO1993010784A1 (en) * 1991-11-25 1993-06-10 University Of Michigan Therapeutic composition and method for preventing reperfusion injury
JP3073309B2 (ja) * 1992-03-27 2000-08-07 雪印乳業株式会社 シアル酸結合５−デアザフラビン系化合物

Also Published As

Publication number Publication date
GB9421099D0 (en) 1994-12-07
GB9321558D0 (en) 1993-12-08
ZA948191B (en) 1995-06-08
EE9600057A (et) 1996-10-15
MD960168A (ro) 1998-04-30
BR9407862A (pt) 1997-05-20
OA10579A (en) 2002-06-19
WO1995011028A1 (en) 1995-04-27
CA2123825A1 (en) 1995-04-20
CO4520283A1 (es) 1997-10-15
CA2174552A1 (en) 1995-04-27
AU7943794A (en) 1995-05-08
HRP940688A2 (en) 1997-04-30
CZ113796A3 (en) 1996-11-13
SK50696A3 (en) 1997-01-08
HU9601006D0 (en) 1996-06-28
BG100599A (en) 1997-02-28
MA23356A1 (fr) 1995-07-01
CN1140992A (zh) 1997-01-22
AP9400695A0 (en) 1995-01-31
GB2283913A (en) 1995-05-24
AP620A (en) 1997-10-14
IL111338A0 (en) 1994-12-29
JO1866B1 (en) 1995-12-27
NO961547L (no) 1996-06-19
HUT76322A (en) 1997-08-28
NO961547D0 (no) 1996-04-18
EP0739208A1 (en) 1996-10-30
JPH09505804A (ja) 1997-06-10
UY23844A1 (es) 1995-03-28
PL314008A1 (en) 1996-08-05

Similar Documents

Publication Publication Date Title
MY138860A (en) Hiv protease inhibitors.
ES2058892T3 (es) Uso de omeprazol como agente antimicrobiano.
MD1224B2 (en) Application of nucleoside analogues with 1,3-oxathiolan for treatment of hepatitis B
CL2004002061A1 (es) Compuestos derivados de heterociclos condensados que contienen nitrogeno; composicion farmaceutica; y su uso como agente antiviral, inhubidor de integrasa y como agente anti-vih.
MD1434B2 (en) 1,3-Oxathiolan nucleoside analogues, pharmaceutical composition containing 1,3-oxathiolan nucleoside analogues and method of treatment of the viral infections
ES2157929T3 (es) Beta-d-dioxolano-nucleosidos enantiomeramente puros.
GEP20063799B (en) Tropane derivatives useful in therapy
EP0668720A4 (en) M-EDTA PHARMACEUTICAL PREPARATIONS AND THEIR USE.
BR9913932A (pt) Uso de análogos de glp-1 no tratamento de derrame
ES2188604T3 (es) Inhibidores de proteasa del vih en combinaciones farmaceuticas para eltratamiento del sida.
ES2121000T3 (es) Composicion utilizada como agente terapeutico contra enfermedades hepaticas virales cronicas.
ES2063033T3 (es) Empleo de igf-ii en el tratamiento de la enfermedades de los huesos.
ES2157252T3 (es) Aplicacion del riluzol en el tratamiento del neuro-sida.
ES2174921T3 (es) Inhibidores de la proteasa del vih.
BR9711647A (pt) Novos derivados de ácido dicafeoilquìmico, seu uso, composições com os mesmos e métodos de tratamento usando-os.
AR022250A1 (es) Envase farmaceutico de uso para el tratamiento y prevencion de infecciones por el virus de la hepatitis b, procedimiento para el tratamiento de pacientes o pacientes susceptibles en padecer infecciones por el virus de la hepatitis b.
EP0695184A4 (en) HIV PROTEASE INHIBITORS
ZA991029B (en) Composition and methods for treatment of hiv infections.
ES2182847T3 (es) Nucleosidos y nucleotidos de anillo expandido.
BG100599A (en) Antiviral form and therapeutical method
MY105855A (en) Therapeutic nucleotides.
CA2100066A1 (en) Michellamines useful as antiviral agents, composition and method of treatment
ES2105923B1 (es) Composiciones para el tratamiento de una infeccion y una enfermedad causadas por el virus de la hepatitis b (hbv).
MX9300205A (es) Compuestos policiclicos disubstituidos y composicion farmaceutica que los contiene.
ES2148234T3 (es) Composicion farmaceutica a base de flavopereirina y su utilizacion en el tratamiento del virus vih.

Legal Events

Date Code Title Description
FD Application declared void or lapsed